Oragenics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Phase IIa Clinical Trial Patient Dosing Count Quarterly8Target: Complete enrollment of Phase IIa feasibility study in Australia
Cash and Cash Equivalents Quarterly6.1MTarget: Secure additional capital to extend runway beyond year-end 2026
Watch Items
- FDA Type C Meeting Request SubmissionTrigger: Q2 2026 target timelineAction: Verify submission and subsequent FDA feedback regarding the U.S. clinical development path for ONP-002
- Investigational New Drug (IND) Application FilingTrigger: Targeted by end of 2026Action: Monitor regulatory filing to enable initiation of U.S.-based clinical trials in 2027
- Going Concern Status and Capital RunwayTrigger: Cash runway projected only through December 31, 2026Action: Track dilutive financing events, preferred stock conversions, or potential non-dilutive grants to resolve going concern doubts
Research as of 20 Jun 2026